# AB1 in Adult Patients with Sickle Cell Disease (SCD)

> **NCT05261711** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nirmish Shah** · enrollment: 16 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** AB1

## Key facts

- **NCT ID:** NCT05261711
- **Lead sponsor:** Nirmish Shah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-05
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study is terminated prior to its planned completion as anticipated by the protocol due to enrollment completion. Data clean up and analysis is being performed.
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261711, "AB1 in Adult Patients with Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05261711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*